Is There a Role for Quinazoline-Based α (1)-Adrenoceptor Antagonists in Cardio-Oncology ?

Cardiovascular Drugs and Therapy

Volumn 28, Issue 6, 2014, Pages 587-588

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; ERLOTINIB; GEFITINIB; LAPATINIB; PRAZOSIN; QUINAZOLINE DERIVATIVE; TERAZOSIN; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; CARDIOLOGY; HUMAN; HYPERTENSION; LETTER; ONCOLOGY; HEART DISEASES; METABOLISM; NEOPLASMS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; HEART DISEASES; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; QUINAZOLINES; RECEPTORS, ADRENERGIC;

EID: 84909952554     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6552-7     Document Type: Letter

References (25)

1. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–11.
2. Makki N, Thiel KW, Miller Jr FJ. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci. 2013;14:20597–613.
3. Haines I. The war on cancer: time for a new terminology. Lancet. 2014;383:1883.
4. Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N Engl J Med. 2014;370:1478–81.
5. Selvam TP, Kumar PV, Vijayaraj P. Quinazoline marketed drugs. Rev Res Pharm. 2011;1:1–21.
6. Dueñas-González A, García-López P, Herrera LA, Medina-Franco JL, González-Fierro A, Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer. 2008;7:82.
7. Roskoski Jr R. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacol Res. 2014;87C:42–59.
8. Chapman N, Chen CY, Fujita T, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens. 2010;28:1796–803. Erratum in: J Hypertens. 2010 Nov;28 (11):2351.
9. Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR. ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42–8.
10. Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, et al. ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J. 2007;153:42–53.
11. Wolak T, Toledano R, Novack V, Sharon A, Shalev A, Wolak A. Doxazosin to treat hypertension: it’s time to take it personally–a retrospective analysis of 19, 495 patients. J Hypertens. 2014;32:1132–7.
12. Patanè S. Insights into Cardio-oncology: Adrenergic receptor signaling and pathways in breast cancer. Curr Med Res Opin. 2014 http://informahealthcare.com/doi/full/10.1185/03007995.2014.932636
13. Bilbro J, Mart M, Kyprianou N. Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res. 2013;33:4695–700.
14. Hui H, Fernando MA, Heaney AP. The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer. 2008;44:160–6.
15. Park MS, Kim BR, Dong SM, Lee SH, Kim DY, Rho SB. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Oncotarget 2014 Jun 6
16. Petty A, Myshkin E, Qin H, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One. 2012;7:e42120.
17. Kintscher U, Wakino S, Kim S, et al. Doxazosin inhibits retinoblastoma protein phosphorylation and G (1)– > S transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:1216–24.
18. Takara K, Sakaeda T, Kakumoto M, et al. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17:527–33.
19. Xu K, Wang X, Ling PM, Tsao SW, Wong YC. The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway. Oncol Rep. 2003;10:1555–60.
20. Thomas D, Wimmer AB, Wu K, et al. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:462–72.
21. Alberti C. Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance. Eur Rev Med Pharmacol Sci. 2007;11:59–64.
22. Han C, Bowen WC, Michalopoulos GK, Wu T. Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. J Cell Physiol. 2008;216:486–97.
23. Yang YF, Wu CC, Chen WP, Chen YL, Su MJ. Prazosin induces p53-mediated autophagic cell death in H9C2 cells. Naunyn Schmiedeberg Arch Pharmacol. 2011;384:209–16.
24. Lin SC, Chueh SC, Hsiao CJ, et al. Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia. 2007;9:830–9.
25. Liao CH, Guh JH, Chueh SC, Yu HJ. Anti-angiogenic effects and mechanism of prazosin. Prostate. 2011;71:976–84.